Press Release Aug 11 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Prochlorperazine Maleate Tablets. The tablets are indicated for treating various mental health conditions and controlling severe nausea and vomiting. The manufacturing will take place at the company's facility in Ahmedabad SEZ, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Aug 05 2022
- Press Release Aug 04 2022
- Press Release Jul 26 2022
- Press Release Jul 21 2022
- Press Release Jul 18 2022
Later from Zydus Lifesciences
- Press Release Aug 30 2022
- Press Release Aug 31 2022
- Press Release Sep 07 2022
- Press Release Sep 09 2022
- Press Release Sep 12 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences